MAS is involved in coronavirus disease-19 (COVID-19), and the blockade of pro-inflammatory cytokines by an anti-IL-6 or IL-6R antibody, such as Tocilizumab, has already been employed for the treatment of MAS and COVID-19 in patients [116,117]. This evidence concerns the gene MAS1 and COVID-19.